AKT3 and non-small cell lung carcinoma: This discovery not only reveals a noncanonical role of AKT3 in NSCLC cell survival but also offers a novel therapeutic strategy to overcome drug resistance and achieve selective AKT3 degradation, highlighting the immense potential of HyT technology in developing protein-selective degraders.